Resmetirom, which was approved by the Food and Drug Administration (FDA) in March 2024, acts hepatocentrically to accelerate -oxidation, lower atherogenic lipoproteins, and deliver early signals necessary for fibrosis regression, all while largely avoiding systemic thyrotoxic effects
When GLP-1 is administered, it activates the GLP-1 receptors in the body
Multivesicular body A type of late endosome that is formed following the inward budding of the outer endosomal membrane and characterized by the accumulation of vesicles in the lumen
However, if you experience gastrointestinal side effects during dose escalation, it may be prudent to avoid alcohol until these symptoms stabilize, and always follow moderate drinking guidelines when you do consume alcohol
Liu BZ, Raveendran D, Fourlanos S, Chong EW